PRVB - Provention Bio: Undervalued And Overlooked Biotech Company - Diabetes Is Not Going Away Anytime Soon
Data by YCharts
Introduction
Provention Bio (PRVB) is a US biotechnology company developing biologics that target immune-mediated diseases. PRVB's therapeutic initiatives target endocrine diseases, infectious diseases, and respiratory diseases. This report will serve as a thorough overview of PRVB's late-stage clinical asset, Teplizumab (PRV-031), as I strongly believe the company’s valuation is tied to its success.
Teplizumab's At-Risk PHASE II trial showed impressive results in delaying and preventing Type 1 Diabetes (T1D) by a median of three years. Based on this result, PRVB submitted a rolling NDA/BLA submission on April 16, 2020,